explore -WSS

explore

author：knowledge 2025-09-29 01:06:48 - browse：9367

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： IRA could hurt research into orphan drugs for rare diseases

Wikipedia

hotspot

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

New weight loss drugs vying to be the next Wegovy or Mounjaro

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Federal judge rules Oregon’s tough new gun law is constitutional

Private equity could exacerbate cardiology's overuse problem, experts fear

How to make the FDA’s new prescription one

knowledge

explore

explore

In Memoriam: Notable people who died in 2023

Celiac disease study examines precisely how gluten triggers injury

In Memoriam: Notable people who died in 2023

How housing is health care on Long Island

Psychedelics group wrestles with new pharma identity

PEPFAR is under serious threat — and so is global health

United colonoscopy coverage change 'may cost lives,' doctors say

Federal judge rules Oregon’s tough new gun law is constitutional

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress likely to miss an opportunity to fix drug shortages issue

Wikipedia

Private equity could exacerbate cardiology's overuse problem, experts fear

IRA could hurt research into orphan drugs for rare diseases

Care demand spikes challenge UnitedHealth’s provider arm

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Global childhood vaccinations edge closer to pre

Congress likely to miss an opportunity to fix drug shortages issue

Wikipedia

entertainment

hotspot

entertainment